Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study

INTRODUCTION: Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to infants in three distinct...

Descripción completa

Detalles Bibliográficos
Autores principales: Alba, Christopher, Malhotra, Shelly, Horsfall, Stephanie, Barnhart, Matthew E., Bekker, Adrie, Chapman, Katerina, Cunningham, Coleen K., Fast, Patricia E., Fouda, Genevieve G., Freedberg, Kenneth A., Goga, Ameena, Ghazaryan, Lusine R., Leroy, Valériane, Mann, Carlyn, McCluskey, Margaret M., McFarland, Elizabeth J., Muturi-Kioi, Vincent, Permar, Sallie R., Shapiro, Roger, Sok, Devin, Stranix-Chibanda, Lynda, Weinstein, Milton C., Ciaranello, Andrea L., Dugdale, Caitlin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659508/
https://www.ncbi.nlm.nih.gov/pubmed/37986879
http://dx.doi.org/10.1101/2023.11.06.23298184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659508/
https://www.ncbi.nlm.nih.gov/pubmed/37986879
http://dx.doi.org/10.1101/2023.11.06.23298184

Ejemplares similares